Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physiogel A.I. (also known as Calming Relief A.I.) is a hypoallergenic topical skincare product developed by Stiefel (a GSK company) for the treatment of dry, irritated, and reactive skin conditions such as atopic dermatitis and xerosis. Its primary active ingredient is palmidrol (palmitamide MEA), an endogenous fatty acid amide that acts as an anti-inflammatory and anti-pruritic agent by modulating the endocannabinoid system, specifically through the activation of PPAR-alpha. The formulation also incorporates a BioMimic complex containing ceramides (such as ceramide 3), squalane, and lecithin to repair and strengthen the skin's moisture barrier. It is marketed as a preservative-free and fragrance-free cream or lotion suitable for sensitive skin in both adults and children. In 2020, the Physiogel brand was acquired by LG Household & Health Care from GSK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Physiogel A.I..